Q-omics provides the consensus-scored BLOC1S6P1 profile across patient tissues and cancer cell-line models. BLOC1S6P1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, BLOC1S6P1 is differentially expressed in 2, with the highest sampling consensus in CHOL. Additionally, BLOC1S6P1 RNA expression shows 6,383 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, CHOL, and STAD as cancer lineages where BLOC1S6P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BLOC1S6P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BLOC1S6P1 survival associations across molecular data types. BLOC1S6P1 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BLOC1S6P1 RNA expression–survival associations across cancer types. High BLOC1S6P1 expression shows unfavorable associations in LUSC, KIRC, ACC, LUAD and KICH, but favorable associations in STAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .017). Together, the overview and detailed table identify LUSC as the clearest survival context for BLOC1S6P1 RNA expression.
This table summarizes BLOC1S6P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BLOC1S6P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BLOC1S6P1 shows lower tumor expression in THCA and higher tumor expression in CHOL. The CHOL box plot shows higher BLOC1S6P1 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .023).
This table shows molecular features associated with BLOC1S6P1 in patient tissues and cancer cell lines. In patient samples, BLOC1S6P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
